Mitchell E. Levinson - Jul 12, 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Chief Strategy Officer
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol: PLSE
Transactions as of: Jul 12, 2023
Transactions value $: $0
Form type: 4
Date filed: 7/14/2023, 08:25 PM
Previous filing: Jul 6, 2023
Next filing: Nov 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Award		+100K			100K	Jul 12, 2023	Common Stock	100K	$7.08	Direct	F1, F2

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on July 12, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to four tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.
F2	Not applicable.

Content

The option was granted on July 12, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to four tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.

Not applicable.